How to read the TRIUMPH-1 readout when it lands

TRIUMPH-1 enrolls approximately 2,300 adults with obesity (BMI ≥ 30, or ≥ 27 with a weight-related comorbidity) without type 2 diabetes. Participants are randomized to several maintenance-dose arms of retatrutide or matching placebo, with a 76-week treatment period. [1]

The primary endpoint is mean percent change in body weight from baseline at 76 weeks. Secondary endpoints include categorical responder thresholds (≥5%, ≥10%, ≥15%, ≥20%, ≥25% weight loss), changes in waist circumference, and cardiometabolic markers.

What TRIUMPH-1 is not: it is not a head-to-head comparison against tirzepatide or semaglutide. The trial does not include an active comparator — only retatrutide vs. placebo. Cross-trial inference is the only available comparison, with all of the usual caveats.

Phase 2 (NEJM 2023): 24.2% mean weight loss at 48 weeks at the 12 mg dose. [2]

Tirzepatide SURMOUNT-1 (Phase 3): 20.9% at 72 weeks at the 15 mg dose. [3]

Semaglutide STEP 1 (Phase 3): 14.9% at 68 weeks at the 2.4 mg dose.

Three rough zones for interpretation:

• ≥ 24% — Phase 2 effect held in Phase 3 or grew with longer follow-up. Strong success. Coverage will be breathless and largely warranted.
• ~ 22 – 24% — Phase 2 effect modestly attenuated in Phase 3, as is typical. Solidly successful; clearly larger than tirzepatide cross-trial. Best base case.
• ~ 20 – 22% — Comparable to tirzepatide cross-trial. The triple-agonist mechanism may not be delivering meaningful incremental efficacy. Coverage will be mixed.
• < 20% — Significant Phase 2-to-Phase 3 attenuation. Raises questions about the mechanism, the program, and the projected commercial premium.

Important: any number above ~15% is, by historical standards, an excellent obesity-drug result. The bar is high here only because Phase 2 set it that way.

In Phase 2, on the 12 mg dose:

• ≥ 5% weight loss: ~100% of participants
• ≥ 15% weight loss: ~83%
• ≥ 20% weight loss: ~63%
• ≥ 25% weight loss: ~26%

The numbers to watch in TRIUMPH-1: do similar proportions hold at scale? A 24% mean weight loss with 25% of participants achieving ≥25% is a very different story than a 24% mean driven by a smaller cluster of high responders. The categorical breakdown determines how the drug will perform in real-world practice — most patients, most of the time, vs. a hot-and-cold response pattern.

GI events and discontinuation rates

Phase 2 reported 6-16% discontinuation due to adverse events across active dose arms, mostly driven by gastrointestinal events. Phase 3 typically shows similar or slightly lower rates (because larger trials enroll more representative, less-intensive populations). A Phase 3 discontinuation rate meaningfully above 16% on the highest dose would signal a real-world tolerability problem.

The heart-rate signal

Phase 2 reported a modest, dose-dependent increase in resting heart rate. The clinical significance has been debated. TRIUMPH-1 will report mean heart-rate change at primary endpoint and the proportion of participants with significant increases. Numbers consistent with Phase 2 (a few beats per minute) are expected; substantially larger increases would be concerning, particularly with TRIUMPH-3 (cardiovascular disease) reading out separately.

Less common but worth watching

• Pancreatitis-like events. Rare in Phase 2 but Phase 3 will refine the rate.
• Gallbladder events. Class effect of GLP-1 drugs; magnitude relative to placebo matters.
• Hypoglycemia rates. Should remain low in this non-diabetic population.
• Body-composition changes. If reported, the muscle-mass discussion that has dominated GLP-1 commentary will hinge on these numbers.

SURMOUNT-1 ran 72 weeks; TRIUMPH-1 runs 76. Both enrolled adults with obesity without type 2 diabetes. Both used once-weekly subcutaneous dosing. The trials are roughly comparable, but not identical:

• Different patient populations (geography, baseline comorbidities).
• Different titration schedules and dose ranges.
• Different placebo run-in or screening protocols.
• Background diet/exercise counseling intensity may differ.

A 1-3 percentage point gap between TRIUMPH-1 and SURMOUNT-1 is within the noise of cross-trial variability. A 4-6 point gap (e.g., retatrutide 24% vs. tirzepatide 21%) would be consistent with Phase 2 expectations and would likely be taken as confirmation of mechanistic advantage. A larger gap (≥ 7 points) would be exceptional. A smaller gap or none would undercut retatrutide's premium positioning.

• Lilly stock and pharma sector reaction. Will move on the headline within minutes. Initial reaction is rarely the right read; sustained reaction over the next week is.
• Regulatory submission timing. A clean positive readout enables Lilly to file an NDA in the following months. A messy readout could push timelines.
• Commercial pricing.Lilly's eventual list price will be informed by the readout's magnitude. A 24%+ result supports a premium to Zepbound; a weaker result narrows the premium opportunity.
• Competitor strategy. Novo, Boehringer, Amgen, and others will recalibrate their own programs. Expect comparator trials, mechanism doubles-downs, or pricing responses depending on the magnitude.
• Patient access conversations. Insurance coverage debates, Medicare obesity-coverage discussions, and employer-benefit decisions all use trial magnitude as input. The readout will be cited for years.

• "Met primary endpoint" — language Lilly uses when statistical significance is achieved. Says nothing about magnitude on its own.
• "Mean weight reduction of X%" — this is the number that goes everywhere. Note whether it is reported as efficacy estimand (treatment-policy or trial-product) and whether it is placebo-adjusted or not.
• "Treatment-emergent adverse events were consistent with the GLP-1 receptor agonist class" — Lilly boilerplate. Means: no surprises. Real safety detail comes weeks later in the conference presentation and journal publication.
• "Detailed results to be presented at [venue]" — Phase 3 obesity readouts typically appear at ObesityWeek, EASD, or the AHA scientific sessions, with simultaneous NEJM publication.
• "On track to file with the FDA in [period]" — informative when present; absence is itself a signal.